Department of Defense – FY19 Breast Cancer Research Program (BCRP)

February 6, 2019 by kjt5j@virginia.edu

The Department of Defense (DoD) has announced its FY19 Breast Cancer Research Program (BCRP) being managed by the office of Congressionally Directed Medical Research Programs (CDMRP).

All current CDMRP funding opportunities can be accessed  at https://cdmrp.army.mil/funding/prgdefault.

The following award types are available now:

  • Breakthrough Award Levels 1 and 2
    • Investigators at all academic levels (or equivalent).  Applications from senior
      postdoctoral fellows who do not meet the eligibility requirements of the Breakthrough Fellowship Award are encouraged to apply under Funding Levels 1 and 2.
    • Supports promising research that has high potential to lead to or make breakthroughs in breast cancer.  Potential impact of the research may be near-term or long-term, but it must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development.
    • Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application.  Different funding levels, based on the scope of research, are available. It is the responsibility of the PI to select the funding level that is most appropriate for the research proposed. The funding level should be selected based on the scope of the research project, rather than the amount of the budget. The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level:
      • Funding Level 1: Innovative, highrisk/high-reward research that is in the earliest stages of idea development. In order to foster research with clearly defined potential to yield new avenues of investigation, preliminary data are not required. Proof-of-concept is the
        anticipated outcome.
      • Funding Level 2: Preclinical research that is already supported by substantial preliminary or published data and strongly validates clinical translation in well-defined context within the breast cancer landscape.
      • Funding Level 2 – Population Science and Prevention Studies: With compelling justification, population science and prevention studies may request higher levels of funding and an additional year in the period of performance. Such studies may require
        additional resources due to the participation of human subjects and/or use of human biospecimens.
  • Breakthrough Award Level 3
    • Independent investigators at all academic levels (or equivalent).
    • Supports promising research that has high potential to lead to or make breakthroughs in breast cancer.  Potential impact of the research may be near-term or long-term, but it must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development.
    • Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application.  Different funding levels, based on the scope of research are available. It is the responsibility of the PI to select the funding level that is most appropriate for the research proposed. The funding level should be selected based on the scope of the research project, rather than the amount of the budget.  The following is a general description, although not all-inclusive, of the scope of research projects that would be appropriate to propose under this funding level:
    • Funding Level 3: Advanced translational studies with a high degree of project readiness. Where relevant, proof of availability of and access to necessary data, human samples, cohort(s), and/or critical reagents must be provided. If the proposed research would ultimately require US Food and Drug Administration (FDA) involvement, applications must demonstrate availability of and access to clinical reagents (e.g., therapeutic molecules) and patient population(s).  Applications must state a realistic timeline for near-term clinical investigation. Small-scale clinical trials (e.g., first in human; Phase I/Ib) may be appropriate.
  • Breakthrough Award Level 4
    • Independent investigators at all academic levels (or equivalent).
    • Supports promising research that has high potential to lead to or make breakthroughs in breast cancer.
    • Potential impact of the research may be near-term or long-term, but it must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development.
    • Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application.  Different funding levels, based on the scope of research, are available. It is the responsibility of the PI to select the funding level that is most appropriate for the research proposed. The funding level should be selected based on the scope of the research project,  rather than the amount of the budget.  The following is a general description, although not all-inclusive, of the scope of research projects that would be appropriate to propose under this funding level:
    • Funding Level 4: Large-scale projects that will transform and revolutionize the clinical management and/or prevention of breast cancer. Human clinical trials are required. PIs are expected to have experience in successfully leading largescale projects and demonstrated  ability (through personal experience or via a commitment from a collaborating clinical investigator) to implement a clinical project successfully. Where relevant, applications must demonstrate availability of and access to necessary data, human samples, cohort(s), and/or
      critical reagents. For proposed research that will require FDA involvement, project readiness requiremetns at the time of application submission include:  proof of availability of and access to clinical reagents (e.g., therapeutics) that meet regulatory compliance guidelines;
      proof of availability of and access to appropriate subject population(s); validated projections for patient recruitment; and submission of an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application to the FDA, if applicable.
  • Breakthrough Fellowship Award
    • As of the application submission deadline, all eligible PIs must have:
      • Successfully completed the requirements for a doctoral or medical degree, and
      • Been in the laboratory or clinical research setting in which the proposed research is to be performed for no more than 2 years, and
      • A total of less than 4 years’ experience in a postdoctoral fellowship or mentored clinical research training program (excludes any clinical residency or fellowship training).
      • Mentor:  Must have breast cancer research experience, including current funding and recent publications.
    • Supports exceptionally talented, “best and brightest” recent doctoral or medical graduates in pursuit of innovative, highimpact breast cancer research.
    • The scope of the research should include innovative, high-risk/high-reward research in the early stages of idea development or research already supported by preliminary data with the potential to make significant advancements toward clinical translation.
    • Proposed research must have high potential to lead to or make breakthroughs in breast cancer and show evidence of rigorous experimental design, sufficient experimental details, appropriate controls, pitfalls and alternatives, and a statistical plan.
    • Individualized researcher development plan and mentorship should prepare the PI for an independent career at the forefront of breast cancer research or patient care.
    • The PI is not required to have previous experience in breast cancer research.
    • Submission of a Letter of Intent is required prior to full application submission.
  • Distinguished Investigator Award
    • At or above the level of Assistant Professor (or equivalent) and be more than 6 years beyond their last mentored position as of the application submission deadline.
    • Supports established visionary leaders from any field to pursue innovative ideas that could accelerate progress toward ending breast cancer.  Applications must propose research that is a fundamental shift from the PI’s track record of research.
    • Does not support continuation of or incremental change from the PI’s published line of research.
    • If the PI is not an established breast cancer researcher, the application must clearly articulate a motivation and commitment for proposing a fundamental shift in the PI’s research and must include at least one collaborator with breast cancer expertise.
    • High-risk/high-reward projects pursuing innovative new paradigms are encouraged, but not required.
    • Applications must include two or more breast cancer advocates on the research team.
    • Submission of a preproposal is required; application submission is by invitation only.
  • Era of Hope Scholar Award
    • Independent, non-mentored investigator within 6 years of his/her last training position (e.g., postdoctoral fellowship, medical residency, clinical fellowship) as of the application submission deadline.
    • Supports exceptionally talented, earlycareer scientists who have demonstrated that they are the “best and brightest” in their fields through extraordinary creativity, vision, innovation, and productivity.
    • Applications should articulate a vision that challenges current dogma and demonstrates an ability to look beyond tradition and convention.
    • PIs must demonstrate experience in forming effective partnerships and collaborations and exhibit strong potential for future leadership in breast cancer.
    • Experience in breast cancer research is not required; however, the application must focus on breast cancer, and the PI must maintain a 50% dedication of his/her full-time professional effort during the award period to breast cancer research.
    • Applications must include two or more breast cancer advocates on the research team.
    • Submission of a Letter of Intent is required prior to full application submission.
  • Innovator Award
    • Associate Professor or above (or equivalent).
    • Supports visionary individuals who have demonstrated creativity, innovative work, and leadership in any field.
    • Provides opportunity to pursue novel, visionary, high-risk ideas that will accelerate progress toward ending breast cancer.
    • Experience in breast cancer research is not required; however, the application must focus on breast cancer, and the PI must maintain a 50% dedication of his/her full-time professional effort during the award period to breast cancer research.
    • Applications must include two or more breast cancer advocates on the research team.
    • Submission of a preproposal is required; application submission is by invitation only.

Detailed descriptions of the funding opportunities, evaluation criteria, and submission requirements can be found in the Announcements.

The BCRP Program Announcement is available electronically for downloading from the Grants.gov website (https://www.grants.gov), the CDMRP website (https://cdmrp.army.mil/funding/prgdefault) and the electronic Biomedical Research Application Portal (eBRAP) (https://eBRAP.org).

The DMRDP Intramural Funding Opportunity Announcement is electronically available from the CDMRP website (http://cdmrp.army.mil/funding/prgdefault.shtml) and eBRAP (https://eBRAP.org).

Deadline:  letters of intent are due in mid-March.  Check the program documents for exact dates for letters of intent and full applications.

Filed Under: Funding Opportunities